Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity

Abstract

Benzodiazepines exert most of their pharmacological effects by a selective facilitation of the postsynaptic actions of GABA1–3. Clinical4,5, behavioural6,7 and electrophysiological8,9 studies have shown reduced drug response following chronic benzo-diazepine administration. We present here electrophysiological evidence for decreased postsynaptic sensitivity to GABA following chronic benzodiazepine administration as measured by the direct iontophoretic application of GABA and serotonin onto serotonergic cells in the midbrain dorsal raphe nucleus (DRN), known to receive GABAergic input8–12. The subsensitivity to GABA was found to be dose dependent and was seen when diazepam administration was three weeks or longer. Further, acute injection of the specific benzodiazepine antagonist13, Ro15–1788, was found to reverse rapidly the decrease in GABA sensitivity observed in chronically diazepam-treated animals without altering GABA sensitivity in vehicle-treated rats. Decreased response to chronic benzodiazepines does not appear to be consistently related to alterations in the number or affinity of receptors for benzodiazepines14. Our studies of radioligand-binding showed a decrease in the ability of GABA to enhance benzodiazepine binding in cerebral cortical mem branes from chronic diazepam-treated animals without significant changes in benzodiazepine binding site density or affinity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Costa, E. & Guidotti, A. A. Rev. Pharmac. Tox. 19, 531–545 (1979).

  2. 2

    Haefely, W. et al. In GABA-Neurotransmitters (eds Krogsgaard-Larsen, P., Scheel-Krueger, J. & Kofod H.) 357–375 (Munksgaard, Copenhagen, 1979).

  3. 3

    Tallman, J. F., Paul, S. M., Skolnick, P. & Gallager, D. W. Science 207, 274–281 (1980).

  4. 4

    Browne, T. R., In Pharmacology of Benzodiazepines (eds Usdin, E., Skolnick, P., Tallman, J., Greenblatt, D. & Paul, S.) 329–337 (Macmillan, London, 1983).

  5. 5

    Greenblatt, D. J. & Shader, R. J. Drug Metabolism. Rev. 8, 13–28 (1978).

  6. 6

    Rosenberg, H. C. & Chiu, T. H. Eur. J. Pharmac. 70, 453–460 (1981).

  7. 7

    Hironaka, T., Fuchino, K. & Fujii, T. Japan J. Pharmac. 33, 95–102 (1983).

  8. 8

    Waterhouse, B., Moises, H., Yeh, H., Geller, H. & Woodward, D. J. Pharmac. exp. Ther. (in the press).

  9. 9

    Sher, P., Study, R., Mazzetta, J., Barker, J. & Nelson, P. Brain Res. 268, 171–176 (1983).

  10. 10

    Gallager, D. Eur. J. Pharmac. 49, 133–143 (1978).

  11. 11

    Belin, M. et al. Brain Res. 170, 279–297 (1979).

  12. 12

    Nanopoulos, D., Belin, M., Maitre, M., Vincendon, G. & Pujol, J. Brain Res. 232, 375–389 (1982).

  13. 13

    Hunkeler, W. et al. Nature 209, 514–516 (1981).

  14. 14

    Braestrup, C. & Nielsen, M. In Handbook of Psychopharmacology (eds Iversen L. L., Iversen S. D. & Snyder S. H.) 285–384 (Plenum, New York, 1983).

  15. 15

    Andrade, R., VanderMaelen, C. & Aghajanian, G. Eur. J. Pharmac. 291, 161–169 (1983).

  16. 16

    Trulson, M., Preussler, D., Howell, G. & Frederickson, C. Neuropharmacology 21, 1045–1050 (1982).

  17. 17

    Cumin, R., Bonetti, E., Scherschlicht, R. & Haefely, W. Experientia 38, 833–834 (1982).

  18. 18

    Lukas, S. E. & Griffiths, R. R. Science 217, 1161–1163 (1982).

  19. 19

    McNicholas, L. & Martin, W. Fedn Proc. 41, 1639 (1982).

  20. 20

    Lund, J. Scand. J. clin. Lab. Invest. 41, 275–280 (1981).

  21. 21

    Gallager, D. & Tallman, J. Neuropharmacology (in the press).

  22. 22

    Braestrup, C. & Nielsen, M. Adv. Biosci. 31, 221–227 (1981).

  23. 23

    Massotti, M., Alleva, F. R., Balazs, T. & Guidotti, A. Neuropharmacology 19, 951–956 (1980).

  24. 24

    Braestrup, C., Schmiechen, R., Neef, G., Nielsen, M. & Petersen, E. N. Science 216, 1241–1243 (1982).

  25. 25

    Costa, E., Corda, M., Epstein, B., Forchetti, C. & Guidotti, A. In Benzodiazepines: Molecular Biology to Clinical Practice (ed. Costa, E.) 117–146 (Raven, New York, 1983).

  26. 26

    Olsen, R. W. A. Rev. Pharmac. Tox. 22, 45–77 (1982).

  27. 27

    Tallman, J. F., Thomas, J. W. & Gallager, D. W. Nature 274, 383–385 (1978).

  28. 28

    Gallager, D. W. & Bunney, W. E. Naunyn–Schmiedeberg's Arch. Pharmac. 307, 129–133 (1979).

  29. 29

    Lowry, O. H., Rosebrough, M. J., Farr, A. L. & Randall, R. L. J. biol. Chem. 193, 265–275 (1951).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gallager, D., Lakoski, J., Gonsalves, S. et al. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature 308, 74–77 (1984). https://doi.org/10.1038/308074a0

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.